Investor Update: IQ-AI rockets as it receives StoneChecker FDA clearance

Headlines from the Proactive UK newsroom.

IQ-AI (LON:IQAI) has received FDA clearance to market its StoneChecker Software in the US. IQ-AI said it was delighted with the decision.

Synairgen (LON:SNG) is to present biomarker data from the first part of its ongoing Phase II trial of its inhaled interferon beta therapy for COPD at a major European conference this month. Synairgen’s treatment is designed to bolster COPD sufferers’ defences against viral infections such as colds and flu.

Itaconix (LON:ITX) has been rated one of "The Top 50 Companies to Disrupt the World" by Biofuels Digest, the world's most widely-read daily publication on the bioeconomy.

Sareum (LON:SAR), another UK biotech, meanwhile will present details of how one of its discoveries significantly reduces tumour growth in disease models of many cancers next month in Boston. In pre-clinical work, Sareum’s treatment promoted an anti-tumour effect by activating the local immune system to attack cancer cells.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...


Alpha Growth's BlackOak Alpha Growth Fund generates positive returns despite...

Alpha Growth PLC (LON:ALGW) (OTCQB: ALPGF) CEO Gobind Sahney tells Proactive the financial services specialist's BlackOak Alpha Growth Fund produced a 2020 calendar year return of 10.63% and a 13.71% total return since inception in September 2019. Sahney says given the challenges of 2020, its...

11 hours, 19 minutes ago

2 min read